Gilead Buying Kite for $11.9 Billion [News in Brief]

Gilead Sciences will buy Kite Pharma—and its autologous CAR T-cell technology—for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: News in Brief Source Type: research